…
Humana Inc. provides medical and specialty insurance products in the United States. It operates in two segments, Insurance and CenterWell. The Insurance segment offers individual Medicare Advantage products, including health insurance benefits, including wellness programs, chronic care management, and care coordination; individual Medicare stand-alone prescription drug products (PDP); group Medicare advantage and Medicare stand-alone PDP; Medicare supplements; specialty and ancillary insurance comprising dental, vision, life and disability; and administrative services to arrange health care services for active-duty and retired military personnel and dependents, as well as pharmacy benefit managers. Its CenterWell segment operates full-service, value-based senior focused primary care centers under the Conviva Senior Primary Care and CenterWell Senior Primary Care brands; a management services organization; CenterWell Home Health, a home health provider; and OneHome, which manages post-acute patient needs, as well as provides pharmacy and hospice solutions. The company was formerly known as Extendicare Inc. and changed its name to Humana Inc. in April 1974. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Humana Inc is a U.S. health insurer focused on Medicare Advantage while also serving Medicaid and employer groups with coverage and care-management services. Growth may be supported by aging demographics, rising Medicare Advantage enrollment, and expansion into value-based care and integrated delivery that could help control medical costs.
Principal risks are sensitivity to Medicare reimbursement and regulatory changes, medical-cost inflation that can compress margins, and execution risk as the company scales value-based care initiatives.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 1453.00M | 1627.00M | 3320.00M | 3568.00M | 3354.00M |
| Minority interest | -15.00M | -7.00M | 5.00M | 4.00M | -1.00M |
| Net income | 1188.00M | 1207.00M | 2489.00M | 2806.00M | 2933.00M |
| Selling general administrative | 242.00M | 248.00M | 265.00M | - | 10121.00M |
| Gross profit | 18852.00M | 17147.00M | 18046.00M | 80199.00M | 72943.00M |
| Reconciled depreciation | 824.00M | 968.00M | 917.00M | 845.00M | 713.00M |
| Ebit | 2084.00M | 2287.00M | 3813.00M | 3969.00M | 3418.00M |
| Ebitda | 2908.00M | 3255.00M | 4730.00M | 4814.00M | 4131.00M |
| Depreciation and amortization | 824.00M | 968.00M | 917.00M | 845.00M | 713.00M |
| Non operating income net other | - | - | - | 165.00M | 597.00M |
| Operating income | 1453.00M | 1627.00M | 3320.00M | 3969.00M | 3418.00M |
| Other operating expenses | 128211.00M | 116184.00M | 103120.00M | 89302.00M | 79710.00M |
| Interest expense | 631.00M | 660.00M | 493.00M | 401.00M | 326.00M |
| Tax provision | 250.00M | 413.00M | 836.00M | 762.00M | 485.00M |
| Interest income | 631.00M | 660.00M | 493.00M | 401.00M | 326.00M |
| Net interest income | -631.00M | -660.00M | -493.00M | -401.00M | -326.00M |
| Income tax expense | 250.00M | 413.00M | 836.00M | 762.00M | 485.00M |
| Total revenue | 129664.00M | 117811.00M | 106440.00M | 92870.00M | 83064.00M |
| Total operating expenses | 17399.00M | 15520.00M | 14726.00M | 89070.00M | -79646.00M |
| Cost of revenue | 110812.00M | 100664.00M | 88394.00M | 12671.00M | 10121.00M |
| Total other income expense net | -1149.00M | -94.00M | -63.00M | -401.00M | -64.00M |
| Net income from continuing ops | 1203.00M | 1214.00M | 2484.00M | 2802.00M | 2934.00M |
| Net income applicable to common shares | 1188.00M | 1207.00M | 2489.00M | 2806.00M | 2933.00M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 48750.00M | 46312.00M | 46892.00M | 43055.00M | 44343.00M |
| Intangible assets | 1128.00M | 1443.00M | 1693.00M | 1765.00M | 2639.00M |
| Other current assets | 9560.00M | -23139.00M | -23355.00M | 5567.00M | 6493.00M |
| Total liab | 31013.00M | 29867.00M | 30574.00M | 27685.00M | 28240.00M |
| Total stockholder equity | 17657.00M | 16375.00M | 16262.00M | 15311.00M | 16080.00M |
| Other current liab | 6023.00M | -16276.00M | -18253.00M | 9526.00M | -254.00M |
| Common stock | 33.00M | 33.00M | 33.00M | 33.00M | 33.00M |
| Capital stock | 33.00M | 33.00M | 33.00M | 33.00M | 33.00M |
| Retained earnings | 29075.00M | 28317.00M | 27540.00M | 25492.00M | 23086.00M |
| Other liab | - | - | - | 1017.00M | 2371.00M |
| Good will | 9686.00M | 9631.00M | 9550.00M | 9142.00M | 11092.00M |
| Other assets | - | 46479.00M | 47065.00M | 43055.00M | -2335.00M |
| Cash | 4200.00M | 2221.00M | 4694.00M | 5061.00M | 3394.00M |
| Cash and equivalents | 4200.00M | 2221.00M | 4694.00M | 5061.00M | 3394.00M |
| Total current liabilities | 10314.00M | 11257.00M | 11946.00M | 17178.00M | 15074.00M |
| Current deferred revenue | 356.00M | 260.00M | 266.00M | 286.00M | 254.00M |
| Net debt | 8737.00M | 10039.00M | 7575.00M | 6363.00M | 9426.00M |
| Short term debt | 150.00M | 724.00M | 1612.00M | 2390.00M | 2279.00M |
| Short long term debt | 0.00M | 577.00M | 1796.00M | 2390.00M | 2279.00M |
| Short long term debt total | 12937.00M | 12260.00M | 12269.00M | 11424.00M | 12820.00M |
| Other stockholder equity | -10818.00M | -10908.00M | -10312.00M | -8910.00M | -7081.00M |
| Property plant equipment | 2231.00M | 2977.00M | 3540.00M | 3221.00M | 3073.00M |
| Total current assets | 7470.00M | 4925.00M | 6729.00M | 26183.00M | 18400.00M |
| Long term investments | 16834.00M | 19332.00M | 17748.00M | 15010.00M | 14113.00M |
| Net tangible assets | - | - | - | 6169.00M | 4988.00M |
| Short term investments | 15703.00M | 18214.00M | 16626.00M | 13881.00M | 13192.00M |
| Net receivables | 3270.00M | 2704.00M | 2035.00M | 1674.00M | 1814.00M |
| Long term debt | 12369.00M | 11144.00M | 10213.00M | 9034.00M | 10541.00M |
| Inventory | - | - | -32021.00M | - | -6493.00M |
| Accounts payable | 9808.00M | 10273.00M | 10068.00M | 14502.00M | 12795.00M |
| Noncontrolling interest in consolidated entity | - | - | - | 59.00M | 23.00M |
| Accumulated other comprehensive income | -633.00M | -1067.00M | -999.00M | -1304.00M | 42.00M |
| Common stock total equity | - | - | - | 33.00M | 33.00M |
| Retained earnings total equity | - | - | - | 25492.00M | 23086.00M |
| Treasury stock | - | - | - | - | -10163.00M |
| Non currrent assets other | 10832.00M | 7744.00M | 7584.00M | -10501.00M | -28278.00M |
| Non current assets total | 41280.00M | 41387.00M | 40163.00M | 16872.00M | 28278.00M |
| Long term debt total | 12369.00M | 11144.00M | 10213.00M | 9034.00M | 10541.00M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 2982.00M | -2952.00M | -3622.00M | -1006.00M | -1053.00M |
| Change to liabilities | - | - | - | 1019.00M | -65.00M |
| Total cashflows from investing activities | 2273.00M | -2952.00M | -3492.00M | -1006.00M | -6556.00M |
| Net borrowings | 431.00M | 218.00M | 423.00M | -1428.00M | 3764.00M |
| Total cash from financing activities | -1215.00M | -2487.00M | -856.00M | -1914.00M | 3015.00M |
| Change to operating activities | - | - | - | 556.00M | -211.00M |
| Net income | 1203.00M | 1214.00M | 2489.00M | 2802.00M | 2934.00M |
| Change in cash | 1979.00M | -2473.00M | -367.00M | 1667.00M | -1279.00M |
| Begin period cash flow | 2221.00M | 4694.00M | 5061.00M | 3394.00M | 4673.00M |
| End period cash flow | 4200.00M | 2221.00M | 4694.00M | 5061.00M | 3394.00M |
| Total cash from operating activities | 921.00M | 2966.00M | 3981.00M | 4587.00M | 2262.00M |
| Depreciation | 824.00M | 968.00M | 917.00M | 845.00M | 713.00M |
| Other cashflows from investing activities | -82.00M | -461.00M | 210.00M | 114.00M | -5240.00M |
| Dividends paid | 430.00M | 431.00M | 431.00M | -392.00M | -354.00M |
| Change to inventory | - | - | -364.00M | - | 280.00M |
| Change to account receivables | -570.00M | -669.00M | -337.00M | -54.00M | -280.00M |
| Sale purchase of stock | -151.00M | -817.00M | -1573.00M | -2096.00M | -79.00M |
| Other cashflows from financing activities | -1065.00M | -1457.00M | 725.00M | 3574.00M | -337.00M |
| Change to netincome | - | - | - | 201.00M | -828.00M |
| Capital expenditures | 546.00M | 575.00M | 1004.00M | 1120.00M | 1316.00M |
| Change receivables | - | - | - | -54.00M | -280.00M |
| Cash flows other operating | - | - | - | -226.00M | -426.00M |
| Cash and cash equivalents changes | - | - | - | 1667.00M | -1279.00M |
| Change in working capital | -1797.00M | 154.00M | 81.00M | 534.00M | -556.00M |
| Stock based compensation | 241.00M | 207.00M | 175.00M | 216.00M | 180.00M |
| Other non cash items | 375.00M | 615.00M | 486.00M | 290.00M | -1024.00M |
| Free cash flow | 375.00M | 2391.00M | 2977.00M | 3467.00M | 946.00M |
Sector: Healthcare Industry: Healthcare Plans
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
|---|---|---|---|---|---|---|---|
| HUM Humana Inc |
7.15 1.74% |
417.56 | 38.47 | 26.45 | 0.33 | 2.54 | 0.39 |
| UNH UnitedHealth Group Incorporated |
4.00 1.00% |
404.44 | 22.57 | 18.38 | 1.33 | 5.65 | 1.38 |
| CVS CVS Health Corp |
2.90 3.28% |
91.41 | 55.65 | 10.80 | 0.25 | 1.32 | 0.42 |
| ELV Elevance Health Inc |
- -% |
413.75 | 18.47 | 14.58 | 0.45 | 2.05 | 0.56 |
| CI Cigna Corp |
- -% |
295.44 | 11.94 | 8.68 | 0.27 | 1.80 | 0.36 |
Humana Inc. provides medical and specialty insurance products in the United States. It operates in two segments, Insurance and CenterWell. The Insurance segment offers individual Medicare Advantage products, including health insurance benefits, including wellness programs, chronic care management, and care coordination; individual Medicare stand-alone prescription drug products (PDP); group Medicare advantage and Medicare stand-alone PDP; Medicare supplements; specialty and ancillary insurance comprising dental, vision, life and disability; and administrative services to arrange health care services for active-duty and retired military personnel and dependents, as well as pharmacy benefit managers. Its CenterWell segment operates full-service, value-based senior focused primary care centers under the Conviva Senior Primary Care and CenterWell Senior Primary Care brands; a management services organization; CenterWell Home Health, a home health provider; and OneHome, which manages post-acute patient needs, as well as provides pharmacy and hospice solutions. The company was formerly known as Extendicare Inc. and changed its name to Humana Inc. in April 1974. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.
| Name | Title | Year Born |
|---|---|---|
| Mr. Bruce Dale Broussard | Pres, CEO & Director | 1962 |
| Ms. Susan Marie Diamond | Chief Financial Officer | 1974 |
| Mr. Timothy S. Huval | Chief Admin. Officer | 1966 |
| Mr. Timothy Alan Wheatley | Segment Pres of Retail | 1968 |
| Dr. William Kevin Fleming Pharm.D., PharmD, RPh | Chief Corp. Affairs Officer & Segment Pres of Pharmacy Solutions | 1968 |
| Mr. John-Paul William Felter | Sr. VP, Chief Accounting Officer, Principal Accounting Officer & Controller | 1983 |
| Mr. Sam M. Deshpande | Chief Information Officer | 1965 |
| Lisa M. Stoner | VP of Investor Relations | NA |
| Mr. Joseph C. Ventura | Chief Legal Officer | 1977 |
| Amy Fry | Sr. VP of Corp. Communications | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.